Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector in AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

Next Previous
Trial Profile

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector in AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KRIYA 825 (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms the VISION Study; VISION
  • Sponsors Kriya Therapeutics

Most Recent Events

  • 29 Apr 2025 According to Kriya Therapeutics media release, the data from this study will be presented at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will be held May 13 to 17, 2025 in New Orleans, LA
  • 27 Feb 2025 Planned initiation date changed from 9 Jan 2025 to 1 Mar 2025.
  • 27 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top